Teicoplanin levels in bone and joint infections: Are standard doses subtherapeutic?

Drago, 1998, Serum and bone concentrations of teicoplanin and vancomycin: study in an animal model, Drugs Exp Clin Res, 24, 185 Darley, 2004, The use and therapeutic drug monitoring of teicoplanin in the UK, Clin Microbiol Infect, 10, 62, 10.1111/j.1469-0691.2004.00747.x Nathwani, 2003, Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy, J Antimicrob Chemother, 51, 391, 10.1093/jac/dkg061 Graninger, 1995, Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis, Eur J Clin Microbiol Infect Dis, 14, 643, 10.1007/BF01690746 Testore, 2000, Long-term intramuscular teicoplanin treatment of chronic osteomyelitis due to oxacillin-resistant Staphylococcus aureus in outpatients, J Chemother, 12, 412, 10.1179/joc.2000.12.5.412 Greenberg, 1990, Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin, Antimicrob Agents Chemother, 34, 2392, 10.1128/AAC.34.12.2392 LeFrock, 1992, Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA. Eur J Surg, 567, 9 Horstkotte, 2004, Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the Task Force on Infective Endocarditis of the European Society of Cardiology, Eur Heart J, 25, 267, 10.1016/j.ehj.2003.11.008 Wilson, 1994, Use of teicoplanin in community medicine, Eur J Clin Microbiol Infect Dis, 13, 701, 10.1007/BF02276052 Gruneberg, 1999, The role of glycopeptide antibiotics in the treatment of infective endocarditis, Int J Antimicrob Agents, 12, 191, 10.1016/S0924-8579(99)00006-0 Wilson, 2000, Clinical pharmacokinetics of teicoplanin, Clin Pharmacokinet, 39, 167, 10.2165/00003088-200039030-00001 Harding, 2000, Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome, J Antimicrob Chemother, 45, 835, 10.1093/jac/45.6.835 Sato, 2006, Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level, J Infect Chemother, 12, 185, 10.1007/s10156-006-0446-Y Wood, 2000, Comparative safety of teicoplanin and vancomycin, J Chemother, 12, 21 Pea, 2003, Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose, J Antimicrob Chemother, 51, 971, 10.1093/jac/dkg147 Senneville, 2004, Adequate use of teicoplanin in bone and joint infections, Med Mal Infect, 34, S99, 10.1016/S0399-077X(04)90084-4 Rouveix, 2004, Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults, Antimicrob Agents Chemother, 48, 2394, 10.1128/AAC.48.7.2394-2399.2004 Henwood, 2000, Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group, J Antimicrob Chemother, 46, 931, 10.1093/jac/46.6.931 Schaison, 2000, Teicoplanin in the treatment of serious infection, J Chemother, 12, 26, 10.1080/1120009X.2000.11782315 LeFrock, 1999, Teicoplanin in the treatment of bone and joint infections: an open study, J Infect Chemother, 5, 32, 10.1007/s101560050005 Babalola, 2004, Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities, J Antimicrob Agents, 23, 343, 10.1016/j.ijantimicag.2003.09.017 Thamlikitkul, 1991, Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase negative staphylococci by time-kill method, J Med Assoc Thai, 74, 669 Yzerman, 1998, Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus, J Antimicrob Chemother, 42, 233, 10.1093/jac/42.2.233 Biavasco, 2000, Glycopeptide resistance in coagulase-negative staphylococci, Eur J Clin Microbiol Infect Dis, 19, 403, 10.1007/s100960000299 Harding, 1998, Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci, J Antimicrob Chemother, 21, 93, 10.1093/jac/21.suppl_A.93 Wilson, 2006, In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients, J Antimicrob Chemother, 58, 470, 10.1093/jac/dkl233